Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2004 1
2005 3
2006 2
2007 1
2008 1
2009 1
2010 1
2011 1
2015 2
2016 2
2017 2
2019 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.
Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, Gottardo R, Bica MA, Garofano A, Koch SD, Fotin-Mleczek M, Hoerr I, Clemens R, von Sonnenburg F. Alberer M, et al. Among authors: hoerr i. Lancet. 2017 Sep 23;390(10101):1511-1520. doi: 10.1016/S0140-6736(17)31665-3. Epub 2017 Jul 25. Lancet. 2017. PMID: 28754494 Clinical Trial.
A successful founder off the beaten path.
Hoerr I. Hoerr I. Nat Biotechnol. 2017 Oct 11;35(10):900-903. doi: 10.1038/nbt.3975. Nat Biotechnol. 2017. PMID: 29019989 No abstract available.
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.
Sebastian M, Schröder A, Scheel B, Hong HS, Muth A, von Boehmer L, Zippelius A, Mayer F, Reck M, Atanackovic D, Thomas M, Schneller F, Stöhlmacher J, Bernhard H, Gröschel A, Lander T, Probst J, Strack T, Wiegand V, Gnad-Vogt U, Kallen KJ, Hoerr I, von der Muelbe F, Fotin-Mleczek M, Knuth A, Koch SD. Sebastian M, et al. Among authors: hoerr i. Cancer Immunol Immunother. 2019 May;68(5):799-812. doi: 10.1007/s00262-019-02315-x. Epub 2019 Feb 15. Cancer Immunol Immunother. 2019. PMID: 30770959 Clinical Trial.
Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy.
Rittig SM, Haentschel M, Weimer KJ, Heine A, Müller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P. Rittig SM, et al. Among authors: hoerr i. Oncoimmunology. 2015 Oct 29;5(5):e1108511. doi: 10.1080/2162402X.2015.1108511. eCollection 2016 May. Oncoimmunology. 2015. PMID: 27467913 Free PMC article.
Characterization of the ribonuclease activity on the skin surface.
Probst J, Brechtel S, Scheel B, Hoerr I, Jung G, Rammensee HG, Pascolo S. Probst J, et al. Among authors: hoerr i. Genet Vaccines Ther. 2006 May 29;4:4. doi: 10.1186/1479-0556-4-4. Genet Vaccines Ther. 2006. PMID: 16732888 Free PMC article.
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.
Kübler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, Parmiani G, Hampel C, Wedel S, Trojan L, Jocham D, Maurer T, Rippin G, Fotin-Mleczek M, von der Mülbe F, Probst J, Hoerr I, Kallen KJ, Lander T, Stenzl A. Kübler H, et al. Among authors: hoerr i. J Immunother Cancer. 2015 Jun 16;3:26. doi: 10.1186/s40425-015-0068-y. eCollection 2015. J Immunother Cancer. 2015. PMID: 26082837 Free PMC article.
19 results